Clinical Trial Focuses on Vaccine Treatments for Tumors | Women, African-Americans at Higher Risk of Heart Attack from Atrial Fibrillation | Researcher Seeks Low-Cost Sterilization Method for Dogs and Cats | Findings Support Intentional Weight Loss for Older Adults | Reducing Stress through Meditation May Help Slow Alzheimer’s | What Works for Women Doesn’t Work for Men | Wake Forest Baptist/Virginia Tech Football Head Impact Study Is Largest Ever | Stem Cells in Urine Could Lead to New Therapies | Compound Shows Promise for Saving Tissue after Severe Injury | Full Research Articles
Clinical Trial Focuses on Vaccine Treatments for Tumors
The study evaluates AGS-003, an investigational, personalized immunotherapy designed to stimulate a tumor-specific T-cell response. In order to determine AGS-003’s potential for extending overall survival in newly diagnosed metastatic renal cell carcinoma patients, it will be evaluated in combination with standard surgery followed by targeted drug therapy.
In the study, a patient is treated by the medical oncologist, the kidney is removed by the urologist, a vaccine is made from the patient’s tumor cells by a basic scientist and then the immunotherapy is administered by the team in surgical oncology.
Secondary endpoints of the study include progression-free survival, safety, overall response and immune response.
“This trial is a great example of personalized medicine and really highlights multidisciplinary efforts in taking care of patients with advanced cancers,” said John H. Stewart IV, MD, associate professor of surgery, associate dean for clinical research and innovation, and the principal investigator for the Wake Forest Baptist study site.
© 2014 Wake Forest Baptist Medical Center | Office of Development and Alumni Affairs | P.O. Box 571021 | Winston-Salem, NC 27157-1021 | All Rights Reserved.